³Ô¹ÏÍøÕ¾

A new mobile app can help clinicians determine which patients with the novel coronavirus (COVID-19) are likely to have severe cases. Created by researchers at NYU College of Dentistry, the app uses artificial intelligence (AI) to assess risk factors and key biomarkers from blood tests, producing a COVID-19 “severity score.”

Current diagnostic tests for COVID-19 detect viral RNA to determine whether someone does or does not have the virus-but they do not provide clues as to how sick a COVID-positive patient may become.

“Identifying and monitoring those at risk for severe cases could help hospitals prioritize care and allocate resources like ICU beds and ventilators. Likewise, knowing who is at low risk for complications could help reduce hospital admissions while these patients are safely managed at home,” said , professor of biomaterials at NYU College of Dentistry, who led the research.

“We want doctors to have both the information they need and the infrastructure required to save lives. COVID-19 has challenged both of these key areas.”

Creating a Severity Score

Using data from 160 hospitalized COVID-19 patients in Wuhan, China, the researchers identified four biomarkers measured in blood tests that were significantly elevated in patients who died versus those who recovered: C-reactive protein (CRP), myoglobin (MYO), procalcitonin (PCT), and cardiac troponin I (cTnI). These biomarkers can signal complications that are relevant to COVID-19, including acute inflammation, lower respiratory tract infection, and poor cardiovascular health.

The researchers then built a model using the biomarkers as well as age and sex, two established risk factors. They trained the model using a machine learning algorithm, a type of AI, to define the patterns of COVID-19 disease and predict its severity. When a patient’s biomarkers and risk factors are entered into the model, it produces a numerical COVID-19 severity score ranging from 0 (mild or moderate) to 100 (critical).

The model was validated using data from 12 hospitalized COVID-19 patients from Shenzhen, China, which confirmed that the model’s severity scores were significantly higher for the patients that died versus those who were discharged. These , a journal of the Royal Society of Chemistry.

As New York City emerged as the epicenter of the pandemic, the researchers further validated the model using data from more than 1,000 New York City COVID-19 patients. To make the tool available and convenient for clinicians, they developed a mobile app that can be used at point-of-care to quickly calculate a patient’s severity score.

A Clinical Decision Support Tool

The app has been retrospectively evaluated in the in Brooklyn, which serve more than 102,000 patients each year as one of the nation’s largest Federally Qualified Health Center networks.

“Real time clinical decision support tools for COVID-19 can be extremely helpful, particularly in the outpatient setting, to help guide monitoring and treatment plans for those at greatest risk,” said , chief medical officer for the Family Health Centers at NYU Langone and a co-author on the Lab on a Chip study.

After optimizing the clinical utility of the app at the Family Health Centers at NYU Langone in May, the researchers aim to roll it out nationwide in the coming weeks. It is possible that the COVID-19 severity score could be integrated with electronic health records, thereby providing clinicians with actionable information at an early stage for those diagnosed with COVID-19.

“We hope this tool can help identify those at high risk for adverse outcomes and reduce the health disparities present with COVID-19,” said Larry K. McReynolds, executive director for the Family Health Centers at NYU Langone.

Building on Innovations in Testing

The COVID-19 severity score leverages a model McDevitt previously developed to predict outcomes for patients with cardiac disease. Cardiac health is one of several priorities of McDevitt’s lab, which creates point-of-care diagnostic systems that can be programmed to test for oral cancer, cardiac disease, and now COVID-19 biomarkers.

The diagnostic system uses small, non-invasive samples-such as swabs of saliva or drops of blood from a fingertip-which are added to credit card-sized cartridges armed with bio-nano-chips pioneered by McDevitt. The cartridge is inserted into a portable analyzer that simultaneously tests for a range of biomarkers, with results available in less than half an hour.

Because this technology is currently used for research and informational purposes only, the COVID-19 app can be used with existing laboratory tests and requires oversight by an authorized clinician. However, over the next few months, McDevitt’s laboratory, in partnership with SensoDx, a company spun out of his lab, plans to develop and scale the ability to test a drop of blood for COVID-19 severity biomarkers-similar to how a person with diabetes tests their blood sugar-and produce a severity score on the spot.

“With COVID-19, point-of-care testing, coupled with a decision support system, could improve how clinicians triage patients-and potentially improve their outcomes, particularly for those who need more immediate and aggressive care,” said McDevitt.

In addition to McDevitt’s research group at NYU College of Dentistry, the study involved collaborators from NYU Grossman School of Medicine, NYU Tandon School of Engineering, Zhongnan Hospital of Wuhan University, and Latham BioPharm Group. The app was developed by McDevitt’s laboratory and OraLiva, a company founded by McDevitt, and is available for both Apple and Android devices. The app is designated for use by authorized clinicians and is not intended for general use by patients.

Funding for the research was provided by the ³Ô¹ÏÍøÕ¾ Institute of Dental and Craniofacial Research (3U01DE017793-02S1 and 5U01DE017793-2).